68 results about "Immunostimulant" patented technology

Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and / or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and / or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and / or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.

The invention relates to the technical field of biological medicine, and discloses a nano composite adjuvant as well as a preparation method and application thereof. The composite adjuvant mainly comprises a TLR9 agonist CpG ODN, a nanoscale liposome, a cationic lipid DOTAP and a high-efficiency immunologic stimulant QS-21, several adjuvant components are prepared into the stable and uniform nanoscale liposome by adopting a microfluidic synthesis method, CpG is wrapped inside the nanoscale liposome, QS-21 is adsorbed outside the nanoscale liposome, a stable immunologic stimulation compound is formed, and the immunologic stimulant can be used for immunologic detection of the TLR9 agonist CpG ODN, the cationic lipid DOTAP and the high-efficiency immunologic stimulant QS-21. All the components have a remarkable synergistic effect, and are matched with corresponding antigens to generate strong and lasting cellular immune and humoral immune responses.

The invention discloses an immunogenic composition containing a composite adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises a gE-gI fusion protein, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the gE-gI fusion protein comprises a VZV gE, a connecting peptide and a VZV gI. The immunogenic composition provided by the invention only contains one immunopotentiator, can be applied to VZV vaccines, and solves the problems of relatively weak gE immunogenicity and relatively large clinical side reaction of the vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, but the vaccine contains fewer immunopotentiators and has lower clinical side effects; in addition, the vaccine can also induce a gI specific antibody and gI specific CMI reaction, which is beneficial to further improvement of the effectiveness of the vaccine. In short, the immunogenic composition has good clinical application potential.

The invention discloses an immune agonist and a preparation method thereof, and relates to the technical field of immune agonist preparation, and the preparation method of the immune agonist comprises the following specific steps: S1, preparing a double-target immune agonist monomer; s2, preparing a cationic liposome inner core; s3, biomimetic cell membrane coating; and S4, finished product detection. According to the immune agonist and the preparation method thereof, in the preparation process, a continuous flow microreactor is used for two-step synthesis of a double-target monomer, a segmented precise temperature control mode is matched with microwave strengthening, the reaction period can be shortened, efficient entrapment of the agonist is achieved through a micro-reaction technology, and the problems that a traditional batch method is low in entrapment efficiency and uneven in particle size are solved; in addition, MDC cell membrane extraction is conducted through differential centrifugation, the integrity of the membrane is guaranteed, active targeting of a CD11c marker on the surface of the MDC cell membrane is achieved through a cell biomimetic membrane, and after lipidosome and membrane vesicles with the volume ratio being 3: 1 are fused, the in-vitro BMDC binding rate is increased compared with that of naked lipidosome.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and / or optionally one or more additional anti-cancer agents.

The present invention relates to compositions comprising an inactivated Mycobacterium or an immunogenic fraction thereof, for use in the prevention of an infection in a subject, wherein the infection is selected from the group consisting of a protozoan parasitic infection and a bacterial infection, with the proviso that the infection is not caused by a Mycobacterium.

Provided is an adjuvant composition comprising a glycoarchaeol and at least one immunostimulant selected from a Toll-like receptor (TLR) agonist and a saponin. The glycoarchaeol and / or immunostimulant may be present as a pharmaceutically acceptable salt. The adjuvant composition may be comprised together with an antigen in an immunogenic composition, such as a vaccine composition, which may be for use to induce an immune response in a subject. Further provided is use of the immunogenic composition to induce an immune response in a subject, particularly an immune response that comprises both a cell-mediated response and a humoral response.

The application belongs to the application field of selenium polysaccharide, and particularly relates to application of the selenium polysaccharide in preparation of an immune active agent, wherein the selenium polysaccharide is obtained by treating Cyclobalanopsis glauca with exogenous selenium, has good immune activity, can better promote proliferation and phagocytosis of RAW264.7 macrophages, and has a significant advantage in improving the release amount of NO, and the results show that the polysaccharide after exogenous selenium strengthening has better immune activity. Exogenous selenium strengthening obviously improves the characteristics of the selenium polysaccharide in Cyclobalanopsis glauca leaves, and has better potential in antioxidation and immune improvement, and provides data support for further research and utilization.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

A hetero-structured RNA with two 3′-overhangs and use thereof as an immune stimulant are provided.

The invention provides a personalized cancer vaccine based on apoptosis vesicles and a preparation method and application thereof, and belongs to the technical field of biological medicine, the personalized cancer vaccine comprises apoptosis vesicles, an immunologic stimulant and a biocompatibility carrier; the apoptosis vesicles are extracellular vesicles generated after tumor cells are subjected to apoptosis induction; the biocompatible carrier is a modified chitosan hydrogel, and the biocompatible carrier is a modified chitosan hydrogel; the immunologic stimulant is loaded in the apoptosis vesicle, and the apoptosis vesicle loaded with the immunologic stimulant is embedded into the modified chitosan hydrogel. According to the invention, apoptosis vesicles generated by induction of tumor cells of a patient are taken as a core, the apoptosis vesicles have a natural tumor antigen library and a strong immune activation capability, and personalized precise treatment can be realized; meanwhile, the invention provides a preparation method and application in postoperative tumor recurrence prevention and treatment, and provides technical support for clinical transformation.

The present disclosure relates in part to methods of treating a solid tumor in a subject in need thereof, the method comprising administering to the subject a retinaldehyde dehydrogenase 1 (RALDH1) inhibitor and an immunostimulator. The present disclosure further relates to pharmaceutical compositions comprising an RALDH1 inhibitor and an immunostimulator.

The invention discloses a composite milk adjuvant, a preparation method and application of the composite milk adjuvant in vaccines, and belongs to the technical field of medicines. The technical problems to be solved are relatively weak cell immunocompetence, relatively poor immunogenicity and relatively weak immunoregulation capability. According to the technical scheme, squalene, polyoxyethylated castor oil 35 and poloxamer 407 are used as raw materials to prepare a basic formula of the milk adjuvant, an immunologic stimulant is added on the basis to prepare the composite milk adjuvant, and the physicochemical properties and safety of the composite milk adjuvant are represented. The synergistic effect of the milk adjuvant on humoral immunity and cellular immunity is further evaluated by being matched with a recombinant tuberculosis antigen Ag85B to immunize mice, and data support is provided for application of the milk adjuvant in development of novel vaccines such as tuberculosis vaccines and the like. The composite milk adjuvant prepared by the invention not only keeps good humoral immunity and induces generation of high-level IgG1 and IgG2a, but also remarkably improves the response level of cellular immunity.

The present invention relates to cancer immunotherapy. In particular, the present invention provides methods, compounds, compositions and kits for treating and / or preventing cancer. Specifically, provided are methods for the treatment of cancer comprising administering a TLR2 agonist, such as a conjugate of dipalmitoyl-S-glyceryl-cysteine (Pam2Cys) and polyethylene glycol (PEG), more specifically a Pam2Cys-Ser-PEG compound, and an immunostimulatory agent, such as an anti-PD-1, anti-PDL-1, anti-PL-1, or anti-CTLA-4 immunotherapeutic agent.

A hetero-structured RNA with two 3′-overhangs and use thereof as an immune stimulant are provided.

The present disclosure relates to a method for predicting the response of a metastasis to immunotherapy in a metastatic colorectal cancer patient. The present disclosure also encompasses an immunotherapy for use in the treatment of a metastatic colorectal cancer in a patient in need thereof previously identified as having a metastasis responsive to immunotherapy and an immune-stimulating agent for use in the treatment of a metastatic colorectal cancer in a patient in need thereof previously identified as having a metastasis non-responsive to immunotherapy. The present disclosure also relates to a pharmaceutical composition comprising an immune-stimulating agent and retinoic acid for use in the treatment of a metastatic colorectal cancer in a patient in need thereof.

The present application provides an immunostimulant containing Lactobacillus helveticus, wherein the Lactobacillus helveticus has three functions: activation of dendritic cell-like cells, induction of immunoglobulin A (IgA) production, and induction of interleukin-12 (IL-12) production.

The present invention provides a method of identifying an animal for which antibiotic treatment, anti-infective treatment, probiotic treatment, immunostimulant treatment, additional monitoring and / or a separate or alternative management strategy is appropriate, comprising: a) collecting a sample from said animal; b) performing a leukocyte differential cell count on said sample; c) comparing said leukocyte differential cell count of (b) with an index of infection; and d) initiating antibiotic treatment, anti-infective treatment, probiotic treatment, immunostimulant treatment, additional monitoring and / or a separate or alternative management strategy of said animal on the basis of said comparing step.

A pharmaceutical composition, a radiotherapy sensitizer, an immunopotentiator or an immunostimulatory agent comprising a metallosome comprising metal nanoparticles and a bacterial component attached thereto, and uses thereof in immunoregulation and tumor treatment are provided.

The invention provides a lipidoid Toll-like receptor agonist derivative as well as preparation and application thereof, and particularly provides a compound as shown in a formula I, a preparation method of the compound and application of the compound as a TLR7 and / or TLR8 agonist. The compounds can be used as immunostimulators and adjuvants.

The present invention relates to a composition for enhancing immunity, comprising, as an active ingredient, an enzyme-treated product of polysaccharides derived from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified fraction thereof. According to the present invention, the composition for enhancing immunity, comprising, as an active ingredient, an enzyme-treated product of polysaccharides from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified fraction thereof, comprises specific types and contents of sugars. Thus, when macrophages, splenocytes, and NK cells are treated with the composition, the composition significantly increases the activities thereof, and therefore can be applied as an immunostimulant or a food composition for enhancing immunity.

The present disclosure provides for compounds including modified saponin compounds, pharmaceutical compositions including modified saponin compounds, methods of use of the modified saponin compounds and the pharmaceutical compositions, methods of making modified saponin compounds, and the like. Compounds and pharmaceutical compositions of the present disclosure can be used in combination with one or more other therapeutic agents for treating viral infection and other diseases.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and immunostimulatory agent(s) bound to its surface are provided. The nanostructures can be, for example, in the form of a 6-helix bundle, or icosahedron, or a pentagonal bipyramid. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be a TLR agonist, such as a TLR9 agonist. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses, and for targeted induction of TLR activation are also provided.

The present disclosure relates, in part, to a method of treating a solid tumor in a subject in need thereof, the method comprising administering to the subject a retinol dehydrogenase 1 (RALDH1) inhibitor and an immunostimulatory agent. The present disclosure further relates to a pharmaceutical composition comprising a RALDH1 inhibitor and an immunostimulatory agent.

The present application provides novel compounds or pharmaceutically acceptable salts thereof having TLR4 activating effects, and useful as immunostimulants or adjuvants in vaccine or allergen immunotherapy. The present application provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof. In the formula (I), X, Y, Z and n are each as defined in the specification.[Formula 1]

To provide a composition for immunostimulation.SOLUTION: A composition for immunostimulation comprising, as an active ingredient, a bacterium phagocytosed by plasmacytoid dentritic cells (pDCs) to a predetermined degree or more and / or a bacterium binding to BDCA2.SELECTED DRAWING: None

Provided are conjugates that can be used for insitu cancer vaccination, such as for cancers with limited accessibility (e.g., lung cancer, pancreatic cancer, renal cancer, etc.) and metastatic disease in situations where the primary tumor has been surgically resected.SOLUTION: Provided are complexes comprising a knottin peptide comprising a modified loop that binds to a cell surface molecule and an immunostimulatory agent conjugated to the knottin peptide via a linker. In some embodiments, the immune stimulating agent activates a pathogen recognition receptor (PRR). For example, the immunostimulatory agent can be a toll-like receptor (TLR) agonist, e.g., an agonist of TLR7, TLR8, and / or TLR9. Also provided are compositions (e.g., pharmaceutical compositions) comprising the complexes of the disclosure, as well as kits comprising such compositions and methods of using such compositions, e.g., to treat an individual having cancer.SELECTED DRAWING: Figure 1

This provides a novel material with immunostimulatory properties. [Solution] An immunostimulant comprising the cells of Pichia yeast or Torraspora yeast as an active ingredient; an immunostimulant food composition, an immunostimulant pharmaceutical composition, or an immunostimulant cosmetic composition comprising the immunostimulant; Pichia yeast with receipt number NITE AP-04248; Pichia yeast with receipt number NITE AP-04249; Torraspora yeast with receipt number NITE AP-04250; Torraspora yeast with receipt number NITE AP-04251.